Compare JAZZ & CPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAZZ | CPB |
|---|---|---|
| Founded | 2003 | 1869 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 9.4B |
| IPO Year | 2007 | N/A |
| Metric | JAZZ | CPB |
|---|---|---|
| Price | $169.80 | $28.63 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 16 |
| Target Price | ★ $199.20 | $32.38 |
| AVG Volume (30 Days) | 1.1M | ★ 7.9M |
| Earning Date | 11-05-2025 | 12-09-2025 |
| Dividend Yield | N/A | ★ 5.46% |
| EPS Growth | N/A | ★ 5.83 |
| EPS | N/A | ★ 1.94 |
| Revenue | $4,157,832,999.00 | ★ $10,158,000,000.00 |
| Revenue This Year | $6.00 | N/A |
| Revenue Next Year | $6.84 | $1.11 |
| P/E Ratio | ★ N/A | $14.74 |
| Revenue Growth | ★ 4.14 | 2.71 |
| 52 Week Low | $95.49 | $27.85 |
| 52 Week High | $182.99 | $43.85 |
| Indicator | JAZZ | CPB |
|---|---|---|
| Relative Strength Index (RSI) | 58.58 | 39.04 |
| Support Level | $164.39 | $28.21 |
| Resistance Level | $172.00 | $29.06 |
| Average True Range (ATR) | 4.28 | 0.75 |
| MACD | -1.26 | -0.02 |
| Stochastic Oscillator | 78.09 | 25.00 |
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Over the past 150-plus years, Campbell's has evolved into a leading domestic packaged food manufacturer, with a portfolio that extends beyond its iconic red-and-white labeled canned soup. In fiscal 2025 (July year-end), snacks accounted for 43% of its revenue, followed by soup (27%), other simple meals (23%), and beverages (7%). Outside its namesake, its brands include Pepperidge Farm, Goldfish, Snyder's of Hanover, Swanson, Pacific Foods, Prego, Pace, V8, and recently acquired Rao's (a deal that closed in 2024). Around 90% of its revenue results from the US and the remainder from Canada and Latin America.